U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Stifel Nicolaus analyst Adam Borg maintained a Hold rating on Rapid7 (RPD – Research Report) today and set a price target of $38.00. The ...

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price ...

MoneyLion operates a “content-as-a-service platform” called mFeed, and Stifel Discover is expected to deliver personalized ...

Onsemi (NASDAQ:ON – Get Free Report) had its price objective reduced by research analysts at Stifel Nicolaus from $60.00 to $52.00 in a research note issued on Tuesday,Benzinga reports. The firm ...

SPS Commerce (NASDAQ:SPSC – Get Free Report) had its price target decreased by analysts at Stifel Nicolaus from $225.00 to $200.00 in a report released on Tuesday,Benzinga reports. The brokerage ...

CEO Jon Congleton highlighted the company's focus on advancing its pivotal trials for lorundrostat, targeting dysregulated aldosterone in patients with uncontrolled and resistant hypertension. He ...

In the eyes of Tesla shareholders, Elon Musk hardly needed another distraction. OpenAI could turn out to be a costly one.

Stifel analysts maintained their Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA), currently trading at $5.24, with a steady price target of $21.00. According to InvestingPro data, analyst targets ...

Stifel analysts adjusted their stance on Exelixis (NASDAQ:EXEL) shares, raising the price target to $36 from the previous $30, while keeping a Hold rating on the stock. The new price target reflects ...